Physician profile
Gisell Mansur
NPI 1053833137
$2,587.21
in general payments reported to CMS, 2019-2025
24 companies · $557 in 2025
The $557 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $382 · 2021: $401 · 2022: $614 · 2023: $166 · 2024: $467 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,189.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $363.48 | 2022-2025 | |
| Abbvie INC. | $296.81 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $289.89 | 2020-2022 | |
| Novo Nordisk INC | $183.96 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $179.68 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $165.85 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Allergan, INC. | $162.92 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $152.03 | 2020-2025 | Eliquis |
| Boston Scientific Corporation | $142.61 | 2024-2025 | Watchman Flx, Watchman Access System |
| Phathom Pharmaceuticals, INC. | $130.68 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $119.80 | 2021-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $94.34 | 2021-2022 | |
| Amgen INC. | $57.90 | 2020-2025 | Repatha, Repatha |
| Pfizer INC. | $43.53 | 2024 | |
| Madrigal Pharmaceuticals | $30.79 | 2025 | Rezdiffra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.14 | 2021-2022 | |
| Glaxosmithkline, LLC. | $27.61 | 2025 | Arexvy, Shingrix |
| Mallinckrodt Hospital Products INC. | $27.56 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.31 | 2023 | Jardiance |
| Phadia US INC. | $14.56 | 2025 | Immunocap |
| Dexcom, INC. | $14.21 | 2024 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $13.70 | 2024 | |
| Radius Health, INC. | $13.18 | 2020 | |
| Sobi, INC | $11.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gisell Mansur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.